Researchers have developed and tested in mice a promising new eye drop formulation for treating dry eye disease. The team reports that the treatment significantly reduced typical dry eye characteristics, such as inflammation, damage to the eye surface and loss of goblet cells, which produce factors that help stabilize tears and lubricate the eye. The findings support conducting human studies to assess the safety and efficacy of this treatment that could potentially benefit millions of people with dry eye disease.

The MAF Test®, developed by the IRB Barcelona and ICREA spin-off Inbiomotion, is now available to oncology and pathology professionals in South Korea and is estimated to benefit around 34,000 new patients each year.

This is the first time a product resulting from research at IRB Barcelona has reached patients in South Korea.

This pioneering test helps oncology professionals predict recurrence and survival rates in breast cancer patients, as well as their potential eligibility to receive treatment with bisphosphonates.

With its entry into South Korea, Inbiomotion reinforces the international projection of the MAF Test® and consolidates a distribution network that already covers Spain, Europe, Africa, and Asia.

The SEOM-GEICAM-SOLTI Clinical Guidelines for early-stage breast cancer recommend the use of the MAF Test® in their 2025 update.